Literature DB >> 6327874

Accessory cell function of human B cells. I. Production of both interleukin 1-like activity and an interleukin 1 inhibitory factor by an EBV-transformed human B cell line.

G Scala, Y D Kuang, R E Hall, A V Muchmore, J J Oppenheim.   

Abstract

In the present paper we report that the ROHA -9 cell line, an Epstein-Barr virus (EBV)-transformed human B cell line with accessory cell capabilities, constitutively secretes a soluble factor with the biochemical and biological characteristics of human monocyte-derived IL-1. The IL-1 derived from ROHA -9 augmented murine thymocyte proliferation and enhanced the proliferative response of human T lymphocytes to concanavalin A (Con A). The ROHA -9-derived IL-1 activity eluted from Sephacryl S-200 in two peaks, at 15- 18K and 32- 35K mol wt, eluted from DEAE-Sephacel at 50-80 and 110-130 mM NaCl, and showed charge heterogeneity with peaks at pI 7.3, 6.1, and 4.1 on isoelectrofocusing (IEF). These findings suggest that B cells may elaborate an IL-1-like activity. During the logarithmic growth of ROHA -9 cells, a inhibitory factor that inhibited the response of mouse thymocytes to IL-1 was also produced. This factor had a mol wt of 95K on Sephacryl S-200, eluted at 150 mM NaCl on DEAE-Sephacel and showed a peak of pI 4.7 on preparative IEF. The inhibitory factor appeared to be selective in its effects on IL-1 responses, since it did not inhibit the activity of IL-2 on mouse thymocytes or on the growth of the IL-2-dependent CT6 cell line. This "contra-IL-1" inhibited the response of murine thymocytes to suboptimal (1 microgram/ml) but not optimal (10 micrograms/ml) doses of Con A and the response of human peripheral blood lymphocytes to streptolysin O ( SLO ) or to alloantigens. Moreover, the factor could be absorbed by mouse thymocytes but not by CT6 cells, and such thymocytes pretreated with contra-IL-1 failed to response to IL-1. Although this inhibitor is the product of a transformed B cell line, it may be representative of regulatory substances that normally control IL-1 activities either at the extracellular or intracellular level.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327874      PMCID: PMC2187324          DOI: 10.1084/jem.159.6.1637

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  32 in total

Review 1.  Dendritic cells: features and functions.

Authors:  R M Steinman; M C Nussenzweig
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

2.  Relationship of cell cycle to recovery of IL 2 activity from human mononuclear cells, human and mouse T cell lines.

Authors:  B M Stadler; S F Dougherty; J J Farrar; J J Oppenheim
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

3.  The role of macrophages in the acute-phase response: SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen.

Authors:  M B Sztein; S N Vogel; J D Sipe; P A Murphy; S B Mizel; J J Oppenheim; D L Rosenstreich
Journal:  Cell Immunol       Date:  1981-09-01       Impact factor: 4.868

4.  Purification to apparent homogeneity of murine interleukin 1.

Authors:  S B Mizel; D Mizel
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

5.  H-2 gene complex restricts transfer of delayed-type hypersensitivity in mice.

Authors:  J F Miller; M A Vadas; A Whitelaw; J Gamble
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

6.  Antigen presentation by human monocytes: evidence for stimulant processing and requirement for interleukin 1.

Authors:  G Scala; J J Oppenheim
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

7.  Identification of a specific interleukin 1 inhibitor in the urine of febrile patients.

Authors:  Z Liao; R S Grimshaw; D L Rosenstreich
Journal:  J Exp Med       Date:  1984-01-01       Impact factor: 14.307

8.  Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells.

Authors:  L H Glimcher; K J Kim; I Green; W E Paul
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

9.  Function of macrophages in antigen recognition by guinea pig T lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes.

Authors:  A S Rosenthal; E M Shevach
Journal:  J Exp Med       Date:  1973-11-01       Impact factor: 14.307

10.  Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s).

Authors:  I Gery; B H Waksman
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

View more
  44 in total

Review 1.  B Cell Activation and Response Regulation During Viral Infections.

Authors:  Jonathan H Lam; Fauna L Smith; Nicole Baumgarth
Journal:  Viral Immunol       Date:  2020-04-23       Impact factor: 2.257

2.  Epstein-Barr virus-containing epithelial cells from nasopharyngeal carcinoma produce interleukin 1 alpha.

Authors:  P Busson; K Braham; G Ganem; F Thomas; D Grausz; M Lipinski; H Wakasugi; T Tursz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

3.  Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies.

Authors:  M Lotz; C D Tsoukas; C A Robinson; C A Dinarello; D A Carson; J H Vaughan
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

4.  Modulation of gingival Langerhans cell T6 antigen expression in vitro by interleukin 1 and an interleukin 1 inhibitor.

Authors:  L J Walsh; G J Seymour; R N Powell
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

5.  Autocrine models of B-lymphocyte growth. I. Role of cell contact and soluble factors in T-independent B-cell responses.

Authors:  J Gordon; G Guy; L Walker
Journal:  Immunology       Date:  1985-10       Impact factor: 7.397

6.  Autocrine models of B-lymphocyte growth. II. Interleukin-1 supports the proliferation of transformed lymphoblasts but not the stimulation of resting B cells triggered through their receptors for antigen.

Authors:  J Gordon; G Guy; L Walker
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

7.  Immunomodulating activity in supernatants from EBV immortalized lymphocytes.

Authors:  B A Blazar; L M Sutton; M Strome
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Release of interleukin 1 inhibitory activity (contra-IL-1) by human monocyte-derived macrophages infected with human immunodeficiency virus in vitro and in vivo.

Authors:  R M Locksley; S Crowe; M D Sadick; F P Heinzel; K D Gardner; M S McGrath; J Mills
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

9.  Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide.

Authors:  T Nishihara; T Koga; S Hamada
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

10.  Uromodulin, an immunosuppressive protein derived from pregnancy urine, is an inhibitor of interleukin 1.

Authors:  K M Brown; A V Muchmore; D L Rosenstreich
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.